BioXcel Therapeutics (BTAI) Gains from Sales and Divestitures (2022 - 2025)
Historic Gains from Sales and Divestitures for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $21000.0.
- BioXcel Therapeutics' Gains from Sales and Divestitures fell 6956.52% to $21000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $21000.0, marking a year-over-year decrease of 6956.52%. This contributed to the annual value of $41000.0 for FY2024, which is 3880.6% down from last year.
- Per BioXcel Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $21000.0 for Q3 2025, which was down 6956.52% from $14000.0 recorded in Q2 2025.
- Over the past 5 years, BioXcel Therapeutics' Gains from Sales and Divestitures peaked at $69000.0 during Q3 2024, and registered a low of $220.0 during Q4 2022.
- In the last 4 years, BioXcel Therapeutics' Gains from Sales and Divestitures had a median value of $41000.0 in 2024 and averaged $37929.1.
- Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 3035454.55% in 2023, then plummeted by 7454.55% in 2025.
- Quarter analysis of 4 years shows BioXcel Therapeutics' Gains from Sales and Divestitures stood at $220.0 in 2022, then skyrocketed by 30354.55% to $67000.0 in 2023, then tumbled by 38.81% to $41000.0 in 2024, then tumbled by 48.78% to $21000.0 in 2025.
- Its Gains from Sales and Divestitures was $21000.0 in Q3 2025, compared to $14000.0 in Q2 2025 and $9000.0 in Q1 2025.